{"id":"eszopiclone-1-mg-elderly","safety":{"commonSideEffects":[{"rate":"10-15%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Somnolence"},{"rate":"5-10%","effect":"Unpleasant taste"},{"rate":"2-5%","effect":"Anxiety"},{"rate":"1-3%","effect":"Hallucinations"},{"rate":"<1%","effect":"Complex sleep behaviors"}]},"_chembl":{"chemblId":"CHEMBL1522","moleculeType":"Small molecule","molecularWeight":"388.82"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Eszopiclone is the active S-enantiomer of zopiclone and acts as a positive allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) in the central nervous system. This potentiation of GABAergic neurotransmission results in sedative, hypnotic effects that facilitate sleep initiation and consolidation. The elderly formulation is specifically dosed at 1 mg to account for age-related pharmacokinetic changes and reduced drug clearance in older populations.","oneSentence":"Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to promote sleep onset and maintenance.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:24.870Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Insomnia in elderly patients (sleep onset and sleep maintenance)"}]},"trialDetails":[{"nctId":"NCT02455271","phase":"","title":"Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia Patients","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2012-10-01","conditions":"Insomnia","enrollment":438},{"nctId":"NCT02452684","phase":"","title":"Investigation of the Safety and Efficacy of Eszopiclone in Insomnia Patients","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2012-10-01","conditions":"Insomnia","enrollment":4876},{"nctId":"NCT00386334","phase":"PHASE4","title":"A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2006-10","conditions":"Insomnia","enrollment":388},{"nctId":"NCT00770692","phase":"PHASE3","title":"A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2008-10","conditions":"Insomnia","enrollment":369}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SEP-190"],"phase":"phase_3","status":"active","brandName":"Eszopiclone 1 mg- Elderly","genericName":"Eszopiclone 1 mg- Elderly","companyName":"Eisai Co., Ltd.","companyId":"eisai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to promote sleep onset and maintenance. Used for Insomnia in elderly patients (sleep onset and sleep maintenance).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}